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Abstract
This study was undertaken to assay the effect of lovastatin on the glycogen synthase kinase-3 beta (GSK-3b) and collapsin
responsive mediator protein-2 (CRMP-2) signaling pathway and mossy fiber sprouting (MFS) in epileptic rats. MFS in the
dentate gyrus (DG) is an important feature of temporal lobe epilepsy (TLE) and is highly related to the severity and the
frequency of spontaneous recurrent seizures. However, the molecular mechanism of MFS is mostly unknown. GSK-3b and
CRMP-2 are the genes responsible for axonal growth and neuronal polarity in the hippocampus, therefore this pathway is a
potential target to investigate MFS. Pilocarpine-induced status epilepticus animal model was taken as our researching
material. Western blot, histological and electrophysiological techniques were used as the studying tools. The results showed
that the expression level of GSK-3b and CRMP-2 were elevated after seizure induction, and the administration of lovastatin
reversed this effect and significantly reduced the extent of MFS in both DG and CA3 region in the hippocampus. The
alteration of expression level of GSK-3b and CRMP-2 after seizure induction proposes that GSK-3b and CRMP-2 are crucial for
MFS and epiletogenesis. The fact that lovastatin reversed the expression level of GSK-3b and CRMP-2 indicated that GSK-3b
and CRMP-2 are possible to be a novel mechanism of lovatstain to suppress MFS and revealed a new therapeutic target and
researching direction for studying the mechanism of MFS and epileptogenesis.
Citation: Lee C-Y, Jaw T, Tseng H-C, Chen I-C, Liou H-H (2012) Lovastatin Modulates Glycogen Synthase Kinase-3b Pathway and Inhibits Mossy Fiber Sprouting
after Pilocarpine-Induced Status Epilepticus. PLoS ONE 7(6): e38789. doi:10.1371/journal.pone.0038789
Editor: Ken Arai, Massachusetts General Hospital/Harvard Medical School, United States of America
Received January 19, 2012; Accepted May 10, 2012; Published June 26, 2012
Copyright:  2012 Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the National Science Council (NSC 96-2323-B-002-014) Taipei, Taiwan. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: hhl@ntu.edu.tw
¤ Current address: Centre Interdisciplinaire de Recherche en Biologie, UMR CNRS 7241/INSERM U1050, Colle `ge de France, Paris, France
Introduction
Temporal lobe epilepsy (TLE) is the most prevalent symptom in
patients who are diagnosed with epilepsy. TLE is mainly caused by
abnormal neuronal circuitry changes in the hippocampal forma-
tion, which is vulnerable to excitotoxicity and easily generates a
focus of spontaneous recurrent seizures (SRS). Several pathological
features have been found in the hippocampal formation under
epileptic condition, including hippocampal sclerosis, massive
amount of neuronal loss caused by either necrosis or apoptosis,
neurogenesis, neuro-inflammation, granule cell dispersion (GCD)
and mossy fiber sprouting (MFS) [1]. Among all these features
caused by epileptic injury, MFS in the dentate gyrus (DG) is the
most important index that is highly correlated with the frequency
of SRS and the severity of TLE [2,3].
Mossy fibers are the axons of granule cells in the DG targeting
to pyramidal cells in the CA3 region. During seizure spreading,
over-excitability induces large amount of glutamate release from
the nerve terminals of mossy fibers and evoked abnormal
discharges on the CA3 pyramidal cells, which further exaggerates
the seizure activities and neuronal damages [4]. After the initial
epileptic injury, mossy fibers lose their targets by the massive
neuronal death in the CA3 area, form incorrect synaptic
connections on the dendrites of granule cells themselves in the
inner molecular layer of the DG, causing a recurrent circuit with
hyper-excitabilities [5,6]. Also, the reduction of MFS is beneficial
to slower the process of epileptogenesis [6]. The mechanism of
MFS is known to related to NMDA receptor [7], new protein
synthesis [8], c-fos signaling [9], neuro-inflammatory factors [10]
and mammalian target of rapamycin (mTOR) pathway [11] by
several pharmacology-based studies. However, the underlying
mechanism of MFS is still not well-understood.
Statins have been taken for non-traditional uses (lipid-lowering
agents) in the treatment of neurological diseases, including stroke
and brain trauma. Clinical trials find that statins reduce the risk of
stroke [12–14] via Akt and its downstream signaling targets
[15,16]. Statins are also reported to restrain kainic acid-induced
seizures and the associated neuro-inflammation and hippocampal
cell death [10,17].
Besides reducing neuro-inflammation, statins also exert neuro-
protective effect by regulating glycogen synthase kinase-3b (GSK-
3b) pathway [15,16]. GSK-3b is one of the downstream genes of
Akt, which is a key molecule in neuronal polarity determination.
Inactivation or down-regulation of GSK-3b enhances axonal
elongation and branching. Active form of GSK-3b reduces axonal
growth by phosphorylation of collapsin response mediator protein-
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e387892 (CRMP-2) [18], which is known to contributes to axonal
pathfinding [19]. Over-expression of CRMP-2 in hippocampal
neurons induces the formation of multiple axons and elongation of
the primary axons [20].
In the present study, we are interested in investigating whether
lovastatin affects the expression of GSK-3b and CRMP-2 in the
TLE animal model and inhibits MFS. Our results showed that the
expression level of GSK-3b and CRMP-2 was increased after in
TLE animal model and the administration of lovastatin reversed
this alteration and effectively reduced the extent of MFS in both
DG and CA3 regions. These findings unveiled a novel mechanism
of lovastatin on MFS.
Materials and Methods
Animal Model of TLE
The pilocarpine-induced status epilepticus (SE) animal model of
chronic epilepsy in rats replicates several characteristics of human
TLE [2,21]. Experimental animals were housed in polycarbonate
boxes (four rats per box) in accordance with the Guide for the Care
and Use of Laboratory Animals by the US National Institutes of
Health. They were maintained in a controlled atmosphere with a
12 h dark/light cycle (lights off at 7:00 PM), a temperature of
2262uC and 50–70% humidity with free access to pelleted feed
and fresh tap water. All efforts were made to minimize animal
suffering and to reduce the number of animal used. The
experiment was approved by the Animal Ethics Committee of
National Taiwan University. Male Wistar rats (around 4–6 weeks
old) were injected with pilocarpine (300–380 mg/kg, INTRA-
PERITONEAL, i.p.) to induce SE. The behavioral seizure was
evaluated according to Racine’s score [22]. SE was defined as
continuous convulsions with a score of 4 to 5 for at least 1 hour
and terminated by pentobarbital (25–30 mg/kg, i.p). The details
of TLE animal model were previously described [23].
Western Blotting
Rat brain tissues were collected from three groups: (1) control
group, (2) 3 and 7 days after SE induction and (3) 3 and 7 days
after SE induction with lovastatin injection. Protein samples were
harvested by lysing hippocampi into lysis buffer supplemented
with protease inhibitor mixture. Protein concentrations were
determined using a Bradford protein assay kit (Bio-Rad, Hercules,
CA, USA). Typically, an aliquot of 10 mg of protein was loaded
into each well of 12% SDS-polyacrylamide gel and separated by
electrophoresis. The proteins were then transferred to nitrocellu-
lose membrane then incubated with indicated antibodies using
standard protocols. Antibodies against GSK-3b, phospho-GSK-3b
(Ser 9) were products from Epitomics (Burlingame, CA, USA).
Antibodies against CRMP-2 were purchased from Cell Signaling
Technology (Danvers, MA, USA). An ECL Plus western blotting
detection system (Amersham Biosciences, Little Chalfont, UK) was
used to obtain western blotting signals, and the autoradiographs
were scanned. The intensity of immunoblot signals was analyzed
by Image J software (http://rsbweb.nih.gov/ij/).
Histology
The animals were kept for 1 month after SE induction and
sacrificed for histological observation during the progression of
MFS. After deep anesthesia with pentobarbital (80 mg/kg, i.p.),
animals were perfused transcardially with 200 ml of sodium sulfide
perfusion medium (2.925 g Na2S, 2.975 g NaH2PO4 in
500 ml H2O) followed by 200 ml 4% paraformaldehyde. The
rat brains were dissected from the cranium and fixed in a glass vial
filled with 4% paraformaldehyde solution for overnight post-
fixation. After fixation, the brains were transferred to phosphate
buffer solution.
The details of Timm’s stain are referred from our previous
publication [23]. The brains were transferred in a 30% sucrose
solution for dehydration until the brains sank to the bottom of the
vials. For histology, 30-mm-thick brain tissue contained hippo-
campus was sectioned by a freezing microtome and then attached
on coated glass slides. We stained one in every six sections,
amounting to approximately 36 sections for each rat, and
calculated the Timm’s scores of these stained sections based on
the following procedures. The sections were developed in the dark
for 45 minutes in a solution of 50% Arabic gum (120 ml), 10 ml
citric acid (51 g/100 ml H2O), 10 ml sodium citrate (47 g/
100 ml H2O), 3.47 g hydroquinone in 60 ml, and
212.25 mg AgNO3. After washing, the slices were dehydrated in
graded alcohol, cleared in xylene, and mounted on slides with
Permount. The Timm’s score in DG was evaluated by the
following criteria: score 0, no granules noted between crest and
tips in the supragranular region; score 1, occasional granules in the
supragranular region occurring in patchy distribution; score 2,
numerous granules in the supragranular region occurring in
patchy distribution; score 3, granules in the supragranular region
occurring in near-continuous distribution; score 4, highly concen-
trated band of granules appearing either in continuous or near
continuous distribution; score 5, continuous dense laminar band of
granules from the crest to the tip of the dentate. In certain
experiments, we also observed the Timm’s score in CA3 area.
Similarly, there are five scores in CA3: score 0, No granules in the
stratum pyramidale or stratum oriens along any portion of the
CA3 subregion; score 1, occasional granules in the stratum
pyramidale or stratum oriens occurring in discrete bundles; score
2, occasional to moderate granules in the stratum pyramidale or
stratum oriens; score 3, prominent granules in the stratum
pyramidale or stratum oriens; score 4, prominent granules in the
stratum pyramidale or stratum oriens occurring in near-continu-
ous distribution along the entire CA3 region; score 5, continuous
or near-continuous dense laminar band of granules in the stratum
pyramidale or stratum oriens along the entire CA3 region [24].
Timm’s score was calculated by each section, averaged from all
the scores of stained sections and taken as one rat’s score for DG
and CA3 accordingly. The stained sections were analyzed for each
rat by one of the authors (CYL) blind to experimental groups and
analyzed by using a semi-quantitative scale for supragranular layer
of the DG and terminal sprouting CA3 pyramidal cell region.
GCD was evaluated by Nissl stain. The slices were obtained as
abovementioned methods. Slices were immersed in 0.1% cresyl
violate solution, and the distances from the inner (hilar) border of
the granule cell layer to the outer border of the most distal granule
cell somata of the DG (thickness of GCD) were measured and
analyzed referring to previous report [25].
Electrophysiology
The electrophysiology was performed based on our previous
study [26]. To performing whole-cell patch-clamp recording,
male Wistar rats (4–6 weeks old) were decapitated under deep
anesthesia with halothane inhalation and the brains quickly
moved to ice-cold oxygenated cutting solution containing (in
mM): 125 NaCl, 2.5 KCl, 0.5 CaCl2, 5 MgCl2, 26 NaHCO3,
15 glucose and aerated to pH 7.4 with 95% O2-5% CO2.
Coronal brain slices (300 mm) containing DG were cut by
microslicer (DTK-1000, Dosaka, Kyoto, Japan) in cutting
solution and then transferred to a holding chamber with
artificial cerebrospinal fluid (ACSF) containing (in mM):
125 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 26 NaHCO3, 15 glu-
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then maintained at room temperature (2362uC) for at least 1 h
before recording. The brain slice was then transferred to the
recording chamber, held submerged and superfused continu-
ously with ACSF at a flow rate of 1–2 ml/min for recording at
room temperature (2362uC). Evoked NMDA receptor-mediated
EPSCs (eEPSCNMDA) were recorded in Mg
2+-free ACSF in the
presence of bicuculline methioide (50 mM), 6-cyano-7-nitroqui-
noxaline-2,3-dione (CNQX, 10 mM), and D-serine (10 mM) at a
holding potential of 270 mV. Patch electrodes were pulled
from standard-walled borosilicate glass capillaries (CSF-150,
Warner Instrument, USA) by micropipette puller (P97, Sutter
Instrument, USA) with a resistance of 3–8 MV, then filled with
a CsCl-based internal solution containing (in mM): 140 CsCl,
9 NaCl, 1 MgCl2, 1 EDTA, 10 HEPES, 5 QX-314, 2 Mg-ATP,
0.3 Na-GTP (pH was adjusted to 7.3 with 1 N CsOH). The
granule cells in DG were visually identified by using an upright
infra-red microscope fitted with a water-immersion lens
(Olympus, Tokyo, Japan). Whole-cell patch-clamp recording
was made from the granule cells in DG of rat brain slices with
an Axopatch 200B amplifier (Axon Instruments, Foster City,
CA, USA). eEPSCNMDA were evoked by a stimulation glass
pipette filled with 3 M NaCl solution was placed on the
molecular layer of DG with a stimulator (S-48, Grass-Telefactor,
USA) and isolation unit (A.M.P.I., Jerusalem, Israel) with a
frequency of 0.1 Hz. eEPSCNMDA were quantified by measuring
peak amplitudes of average responses. The data was acquired
by Clampex 9.0 software (Axon Instruments, Foster City, CA,
USA), stored in the hard drive and analyzed by Clampfit 9.0
(Axon Instruments, Foster City, CA, USA).
Drugs
Bicuculline methioide, dexamethasone, L-NAME, lovastatin,
MK-801, and pentobarbital were purchased from Sigma (St.
Louis, MO, USA). CNQX and D-serine were purchased from
Tocris (Bristol, UK). Drugs for injection were dissolved in 0.9%
NaCl solution and directly administrated subcutaneously 3 hours
after intraperitoneal injection of pentobarbital. Drugs for electro-
physiology were dissolved in double distilled water except CNQX
were dissolved in 100% DMSO as stock solution (the final
concentration of DMSO in ACSF was less than 0.1%). The
dosages for investigation were summarized in Table 1.
Statistics
Statistical differences were established by Student’s t-test, one-
way ANOVA and post-hoc Mann-Whitney U test. Data were
expressed as a mean 6 SE, and P,0.05 was taken to indicate
statistical significance. The n values referred the number of animal
used.
Results
It is known that GSK-3b regulates axonal growth and neuronal
polarity through phosphorylating CRMP-2 [18], therefore we
examined the expression level and phosphorylation state of GSK-
3b and CRMP-2 from control, SE and SE+lovastatin groups,
respectively, by western blotting method. We administrated
lovastatin (20 mg/kg) to the rats 3 hours after terminating SE by
pentobarbital. The experimental regimen is illustrated in
Figure 1A. To determine a proper observation time point of
MFS, we evaluated the Timm’s score from 1 to 3 months after SE
induction. The Timm’s score after SE induction was 0.6060.15 in
control group (n=16), 2.6260.25 in 1 month SE group (n=16,
P,0.001), 2.7160.29 in 2 months SE group (n=7, P,0.001), and
3.4060.40 in 3 months SE group (n=5, P,0.001)(one-way
ANOVA and post-hoc Mann-Whitney U test, regression constant,
0.71) (Figure 1B). Therefore, to minimize the animal suffering and
consumption and to reduce the experimental duration, we chose 1
month as our observation time point to record Timm’s score.
The Expression and Phosphorylation Pattern of GSK-3b
after Seizure Induction and the Administration of
Lovastatin
We firstly examined the total expression level of GSK-3b.A t
day 3 after SE induction, the amount of GSK-3b in both SE
and SE+lovastatin group were about three times higher than
control group (control, 1.0060.20; SE, 3.0460.48; SE+lovasta-
tin 2.8260.35, P,0.05, n=3). At day 7 after SE, the amount
of GSK-3b in SE is similar as control but significantly higher in
SE+lovastatin group (control, 1.0060.07; SE, 0.9960.03;
SE+lovastatin, 1.4260.01, P,0.05, n=3). Furthermore, we
examined the states of serine phosphorylation of GSK-3b
(pGSK-3b). At day 3 after SE, the expression of pGSK-3b in
SE group was about ten times increased than control and was
significantly reversed in SE+lovastatin group (control,
Table 1. Drug administration regimen.
Drugs Dosage (s.c.)
Lovastatin (HMG-CoA inhibitor) 20 mg/kg
MK-801 (NMDA receptor blocker) 0.5 mg/kg
L-NAME (iNOS inhibitor) 20 mg/kg
Dexamethasone (Steroid) 20 mg/kg
All the drugs were injected subcutaneously after SE induction.
doi:10.1371/journal.pone.0038789.t001
Figure 1. The experimental design and Timm’s score recorded
from different time points. (A) The experimental design of TLE
animal model and drug administration. (B) Timm’s score recorded from
control and 1 to 3 months after SE induction. 1 month after SE
induction, the Timm’s score was significantly increased compared with
control group and show an increasing tendency with time. (*compared
with control group).
doi:10.1371/journal.pone.0038789.g001
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n=3). At day 7 after SE, the expression of pGSK-3b slightly
increased in SE group and was significantly decreased in
SE+lovastatin group (control, 1.0060.06; SE, 1.1860.05;
SE+lovastatin, 0.7660.03, P,0.05, n=3) (Student’s t-
test)(Figure 2).
The Expression Level of CRMP-2 after Seizure Induction
and the Administration of Lovastatin
In the next, we examined the expression level CRMP-2, which
is the downstream signal of GSK-3b. At day 3 after SE, the
expression level of CRMP-2 of SE group is higher than control
(1.5260.03, P,0.05, n=3) but the level of CRMP-2 in
SE+lovastatin group was not significantly increased (1.1260.05,
P.0.05, n=3). At day 7 after SE, the amount of CRMP-2 in SE
group is higher than control (1.7160.02, P,0.05, n=3) but the
amount of CRMP-2 in SE+lovastatin group was not significant
changed (1.1160.05, P.0.05, n=3) (Student’s t-test) (Figure 3).
Lovastatin Inhibited MFS
After drug administrated, we recorded the Timm’s score 1
month after SE induction to evaluate the severity of MFS. In our
result, MK-801 and lovastatin significantly reduced Timm’s score
but L-NAME and dexamethasone did not show the similar effect.
The Timm’s score was 0.6060.15 in control group (n=16),
2.6260.25 in SE group (n=16, P,0.001, compared with control
group), 1.4460.56 in SE+MK-801 group (n=6, P,0.05, com-
pared with control group; P,0.05, compared with SE group),
1.2260.31 in SE+lovastatin group (n=12, P,0.05, compared
with control group; P,0.01, compared with SE group), 1.9860.33
in SE+L-NAME group (n=10, P,0.01, compared with control
group; P.0.05, compared with SE group), and 2.8060.35 in
SE+dexamethasone group (n=5, P,0.001, compared with
control group; P.0.05, compared with SE group)(Figure 4, one-
way ANOVA and post-hoc Mann-Whitney U test). We next
observed whether we could find the similar phenomenon in CA3
area. The Timm’s score was 1.3960.16 in control group (n=17),
2.7460.22 in SE group (n=15, P,0.001, compared with control
group), 2.1560.28 in SE+MK-801 group (n=6, P,0.05, com-
pared with control group; P.0.05, compared with SE group),
2.0360.17 in SE+lovastatin group (n=12, P,0.01, compared
Figure 2. Lovastatin significantly alter the expression and phosphorylation pattern of GSK-3b at day 3 and 7 after pilocarpine-
induced SE. The GSK-3b protein expression and phosphorylation levels from control, SE and SE+statin rat hippocampus was determined by western
blot. pGSK-3b indicate the serine phosphorylation of GSK-3b. GAPDH was used as loading control. Lower panel show quantification of the relative
protein amount of GSK-3b and serine phosphorylation level of GSK-3b. (A) The expression level of GSK-3b at day 3 after SE. (B) The expression level of
GSK-3b at day 7 after SE. (*compared with control group; #compared with SE group).
doi:10.1371/journal.pone.0038789.g002
Figure 3. Lovastatin significantly alter the expression pattern
of CRMP-2 at day 3 and day 7 after pilocarpine-induced SE. The
CRMP-2 protein expression levels from control, SE and SE+statin was
determined by western blot. GAPDH was used as loading control. Lower
panel show quantification of the relative protein amount of CRMP-2.
(*compared with control group; #compared with SE group).
doi:10.1371/journal.pone.0038789.g003
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tively (Figure 5, one-way ANOVA and post-hoc Mann-Whitney U
test). This result showed that lovastatin inhibited axonal sprouting
in both DG and CA3 areas after SE induction.
Lovastatin did not Behave as an NMDA Receptor Blocker
At last, we tested whether lovastatin behaves as a NMDA
receptor blocker (like MK-801) to reduce Timm’s score. It is
known that 1 month after SE induction, the thickness of granule
cell layer in the DG is increased (GCD) and could be prevented by
MK-801 [27]. If lovastatin itself is an NMDA receptor blocker,
GCD should be accordingly decreased. In our result, the thickness
of granule cell layer in the DG is 67.362.8 mm in control group
(n=6), 84.964.3 mm in SE group (n=18, P,0.05 compared with
control group), 80.964.3 mmi nS E +lovastatin group (n=12,
P,0.05 compared with control group; P.0.05 compared with SE
group), 67.663.5 mmi nS E + MK-801 group (n=6, P.0.05
compared with control group; P,0.05 compared with SE group)
Figure 4. Timm’s stain under different treatments in the DG. (A) The Timm’s score was significantly increased after SE induction. MK-801 and
lovastatin significantly decreased Timm’s score after SE induction. However, L-NAME and dexamethasone did not show any effect. Scale bar, 200 mm
in the left panels and 100 mm for the right panels. (B) Summary data showing the mean Timm’s score between control and experimental groups in
the DG. (*compared with control group; #compared with SE group).
doi:10.1371/journal.pone.0038789.g004
Figure 5. Timm’s stain under different treatments in the CA3. (A) The Timm’s score was significantly increased after SE induction. MK-801 and
lovastatin significantly decreased Timm’s score after SE induction. Scale bar, 200 mm in the left panels and 100 mm for the right panels. (B) Summary
data showing the mean Timm’s score between control and experimental groups in the CA3. (*compared with control group; #compared with SE
group).
doi:10.1371/journal.pone.0038789.g005
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not show any effect on GDC as MK-801 did.
Furthermore,wedirectlyrecordedeEPSCNMDAfromthegranule
cells in the DG to test whether lovastatin acts on NMDA receptor.
Lovastatin(100 mM)wasbathappliedtothehippocampalbrainslices
and theamplitude ofeEPSCNMDAwererecorded.Accordingtoour
observation, lovastatin did not significantly reduce the mean
amplitude of eEPSCNMDA. The mean amplitude of eEPSCNMDA
after application of lovastatin was 120.4612.6 (% of control, n=3,
P.0.05,Student’s t-test)(Figure 7),indicating thatlovastatin did not
directlyaffectNMDAreceptor-mediatedsynaptictransmissioninthe
DG. The present results demonstrated that lovastatin did not affect
NMDAreceptors.
Discussion
In the present study, we found an increased expression of GSK-
3b, pGSK-3b and CRMP-2 after SE induction. Application
lovastatin reversed the alteration of pGSK-3b/GSK-3b and
CRMP-2 and inhibited MFS. Therefore we propose that
lovastatin inhibited MFS by regulating the expression and
phosphorylation state of GSK-3b and CRMP-2 other than anti-
inflammatory and NMDA receptor blocking effect.
Lovastatin Reversed the Increase of pGSK-3b/GSK-3b
Ratio and CRMP-2 after SE Induction.
Statins are reported to activate the PI3K/Akt pathway, affect
neurogenesis, delay neuronal death, improve spatial learning and
associated with therapeutic improvement after traumatic brain
injury in the DG [15,16]. GSK-3b is one of the genes that
responsible to neuronal survival and axonal growth. The activity
of GSK-3b is negatively regulated by N-terminal phosphorylation
of Ser 9 [28]. The phosphorylation state of GSK-3b controls
neuronal survival and axonal growth [29] through regulating
CRMP-2 [18]. Our data showed that the expression of GSK-3b
was increased and highly phosphorylated at 3 days after SE
induction (Figure 2A), accompanied with an increase of CRMP-2
expression (Figure 3). This could lead to axonal growth and
guidance in the formation of MFS. When applying lovastatin, the
pGSK-3b was decreased but the total GSK-3b was not change,
Figure 6. Nissl stain under different treatments in the DG. (A) After SE, the thickness of granule cell layer was significant increased. After SE
induction, MK-801 significantly decreased the thickness of granule cell layer but lovastatin did not. Scale bar, 100 mm. (B) Summary data showing the
mean thickness of granule cell layer between control and experimental groups in the DG. (*compared with control group; #compared with SE
group).
doi:10.1371/journal.pone.0038789.g006
Figure 7. The effect of lovastatin on the eEPSCNMDA. (A) The eEPSCNMDA was not significantly altered by lovatstatin (100 mM) application. Scale
bar, 20 ms, 100 pA. (B) Summary data showing the mean amplitude of the eEPSCNMDA between control and experimental groups in the DG.
doi:10.1371/journal.pone.0038789.g007
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pGSK-3b/GSK-3b ratio, further to inactivate CRMP-2 and to
inhibit MFS. Although SE-induced phosphorylation of GSK-3b
was not that dramatic at 7 days after SE induction, the
administration of lovastatin still decreased pGSK-3b/GSK-3b
ratio (Figure 2B), to regulate the activity of CRMP-2. Moreover,
according to our observation, in the absence of SE induction,
lovastatin did not show any effect on the expression of GSK-3b
and pGSK-3b, which further supported the idea that lovastatin
regulated the expression of pGSK-3b and GSK-3b only after SE
induction (Text S1 and Figure S1).
The expression of CRMP-2 was accordingly increased at both 3
and 7 day after SE induction (Figure 3), and lovastatin reduced the
expression of CRMP-2, which is consistent with the moderation of
GSK-3b/pGSK-3b ratio by lovastatin. The fact that lovastatin
regulated GSK-3b and CRMP-2 is compatible to explain its anti-
MFS effect. Therefore here we propose that the abnormal
neuronal fiber growth in TLE animal model is possibly caused
by SE induced GSK-3b phosphorylation. Although the relation-
ship between the activation of GSK-3b/CRMP-2 and MFS is not
well established, the fact that administration of lovastatin was able
to reverse this effect and cease neuronal fiber growth still provided
a potential target of statins and a new insight to further understand
the underlying mechanisms of MFS and epileptogenesis, as the
information provided by previous studies [9,11]. Since lovastatin
has not ever been reported as a specific agonist/antagonist as the
other experimental agents, the triangular relationship between
lovatstain, GSK-3b/CRMP-2 and MFS still needs further
investigation. Furthermore, it is noticeable that a similar study
has been reported that atorvastatin inhibits GSK-3b phosphory-
lation by cardiac hypertrophic stimuli [30], supporting our point of
view that statins are able regulate GSK-3b after severe injury and
plays a role in protecting cells from the further damages, in this
case, MFS.
According to the results, at 7 days after SE induction, the
expression level of GSK-3b was not significant with control group,
indicating that this pattern was restricted within the first week after
SE induction. In addition, a hypothesis that the subsequent
pathophysiological alteration is likely initiated at the time of injury
was proposed [31,32]. Evidently, a previous study showed that the
dramatic cytokinic alteration after SE induction take place acutely
in the early phase and is thought dominant to determine the
consequence of epiletogenesis [33]. Therefore, in our experimental
design, we only examined the expression level of GSK-3b/
CRMP-2 restricted to the first week after SE induction. The
alteration for the later stage is waiting for further study.
Neuro-inflammation and the Formation of MFS
Statins are effective neuroprotective agents in several brain
pathological models due to their excellent anti-inflammatory
activity [34]. After SE induction, several pro-inflammatory
cytokines are activated or over-expressed rapidly, such as iNOS
[35], COX-2 [36], tumor necrosis factors and interleukin families
[33]. Drugs which inhibit these inflammatory molecules are
reported to reduce seizure-induced damages [37,38]. After SE
induction, the inflammatory response surges rapidly and drops to
basal level within 2 days [33]. Therefore, at the beginning of our
experimental design, we hypothesized that if we administrated
anti-inflammatory agents (lovastatin, L-NAME and dexametha-
sone) to block the primarily dramatic inflammatory response
immediately after SE induction, which might be able to inhibit the
downstream consequences to prevent or restrict the extent of
MFS. In our experiment, anti-inflammatory drugs were injected
subcutaneously 3 hours after the termination of SE (Figure 1A).
However, the results did not support our hypothesis because L-
NAME and dexamethasone neither show any significant effect on
the expression and phosphorylation level of GSK-3b nor on MFS
as well (Text S1, Figure S1 and 4).
A recent study reported that chronic administration of
simvastatin alters the expression of IL-1, TNF but not IL-6 3
days after kainic acid-induced injury and further inhibits MFS
[10]. However, there is no direct evidence to prove the causation
of neuro-inflammation and MFS. In our study, we could not
totally exclude role of neuro-inflammation in MFS by only single
high dosage administration of anti-inflammatory agents since this
regime might be not strong enough to terminate the robust
activation of neuro-inflammation after SE induction. Besides
comparing the response to anti-inflammatory agents (L-NAME
and dexamethasone), an actual immune system modulation should
be looked at to achieve a conclusions about the role of
neuroinflammation.
Lovastatin did not Mimic the Effect as NMDA Receptor
Antagonist
Lovastatin is reported to reduce NMDA-mediated excitotoxicity
on cultured cortical neurons [39]. NMDA receptor activation is a
common pathway shared by different models of neurologic
diseases. Most brain injuries are firstly ignited by the over-
activation of NMDA receptor, which causes large amount of Ca
2+
influx, injures the neuronal cells, initiates abnormal signals to
further exaggerate cellular damages and recruits pathological
alterations [40]. To block the activation of NMDA receptor
immediately after brain injury is a well-recognized strategy to
protect neuronal cells from further damage. In our study, both
histological and electrophysiological techniques excluded the
involvement of a direct NMDA receptor blocking effect of
lovastatin since lovastatin did not showed any inhibitory effect
on eEPSCNMDA or GCD (Figure 6, 7).
Pharmacological Significance and Clinical Implication
Our present data showed that lovastatin modulated the
expression of GSK-3b and CRMP-2 and inhibited MFS. This
seizure-oriented research added two major contributions to the
current knowledge of neuropharmacology. First, although several
pharmacological tools [2,9,11], and a few antiepileptic drugs [27]
are reported to inhibit MFS, only a handful of them are clinically
available. Our study extends the clinical application of lovastatin
as an anti-MFS agent which is potentially helpful for treating
epilepsy. Second, besides anti-inflammatory effect of statins, we
revealed that GSK-3b and CRMP-2 pathway is also the target of
statins, which provides a new insight to further understand the
underlying mechanisms of MFS and epileptogenesis.
Supporting Information
Figure S1 Lovastatin, L-NAME, and dexamethasone did
not significantly alter the expression and phosphoryla-
tion pattern of GSK-3b in the absence of pilocarpine-
induced SE, determined by western blot. The expression
levels of (A) GSK-3b and (B) pGSK-3b were not changed by
lovastatin, L-NAME, nor dexamethasone, at both day 3 and 7
after drug administration.
(TIF)
Text S1 To examine whether lovastatin itself affects the
total expression level of GSK-3b, we administrated
lovatstain to the rats without SE induction and observed
the expression level of GSK-3b. Also we applied both L-
Lovastatin Inhibits Mossy Fiber Sprouting
PLoS ONE | www.plosone.org 7 June 2012 | Volume 7 | Issue 6 | e38789NAME and dexamethasone to investigate the possible involve-
ment of neuro-inflammatory pathway. In the lovastatin-treated
group, the amount of GSK-3b did not show any difference
between each group (control, 1.0060.14; day 3, 0.9960.11; day 7,
0.8660.16, P.0.05, n=3). In the L-NAME-treated group, the
amount of GSK-3b did not show any difference between each
group (control, 1.0060.10; day 3, 1.0160.02; day 7, 1.2460.12,
P.0.05, n=3). In the dexamethasone-treated group, the amount
of GSK-3b did not show any difference between each group
(control, 1.0060.11; day 3, 1.1860.07; day 7, 0.9060.03,
P.0.05, n=3). In the next we observed the expression level of
pGSK-3b. In the lovastatin-treated group, the amount of pGSK-
3b did not show any difference between each group (control,
1.0060.17; day 3, 1.1760.07; day 7, 0.9060.09, P.0.05, n=3).
In the L-NAME-treated group, the amount of pGSK-3b did not
show any difference between each group (control, 1.0060.10; day
3, 0.9960.03; day 7, 1.0960.07, P.0.05, n=3). In the
dexamethasone-treated group, the amount of pGSK-3b did not
show any difference between each group (control, 1.0060.07; day
3, 1.0860.01; day 7, 1.0960.12, P.0.05, n=3) (Student’s t-
test)(Figure S1).
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